SPIRIVA HANDIHALER
LAMA DPI
Tiotropium bromide · Boehringer Ingelheim
Active Medication & Mechanism
- Tiotropium bromide monohydrate LAMA18 mcg per capsule (delivers a mean of 10.4 mcg from the mouthpiece in vitro at 39 L/min)
Long-acting muscarinic antagonist (anticholinergic). Binds to M1–M3 muscarinic receptors, with slow dissociation from M3 receptors on airway smooth muscle, providing 24-hour bronchodilation.
FDA-Approved Dosing — Strength × Indication
Strength Regimen COPDAsthma
18 mcg
2 inhalations of 1 capsule once daily (entire capsule content) → 18 mcg
FDA Approved
Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.
Not Approved
Spiriva HandiHaler is not FDA-approved for asthma; Spiriva Respimat carries the asthma indication (different product and dose).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
18 mcg 2 inhalations of 1 capsule once daily (entire capsule content) → 18 mcg
COPD FDA Approved
Long-term, once-daily maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Also reduces COPD exacerbations.
Asthma Not Approved
Spiriva HandiHaler is not FDA-approved for asthma; Spiriva Respimat carries the asthma indication (different product and dose).
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Per labeling, a SABA is used.
Related Inhalers
Same active ingredients (Tiotropium)